Opinion

Video

Current Front-Line Targeted Treatments in Ph+ ALL

Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Related Videos
A panel of 4 experts on PNH
A panel of 4 experts on PNH
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute
A panel of 4 experts on biosimilars
A panel of 4 experts on CLL
A panel of 4 experts on CLL
A panel of 5 experts on RSV
A panel of 5 experts on RSV
Related Content
CH LogoCenter for Biosimilars Logo